Argenx SE, a leading biotechnology company headquartered in the Netherlands, is at the forefront of developing innovative therapies for severe autoimmune diseases and cancer. Founded in 2008, Argenx has made significant strides in the industry, particularly with its proprietary antibody engineering platform, which enables the creation of unique therapeutic candidates. The company’s flagship product, efgartigimod, has garnered attention for its potential to transform treatment paradigms in conditions like myasthenia gravis. With a strong presence in Europe and North America, Argenx has established itself as a key player in the biopharmaceutical sector, recognised for its commitment to advancing patient care through cutting-edge science and strategic partnerships.
How does Argenx's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Argenx's score of 44 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Argenx, headquartered in the Netherlands, reported total carbon emissions of approximately 231,769,000 kg CO2e. This figure includes 3,788,000 kg CO2e from Scope 1 emissions, which are direct emissions from owned or controlled sources. Scope 2 emissions, related to the generation of purchased electricity, steam, heating, and cooling, amounted to about 534,000 kg CO2e (market-based). The majority of their emissions, approximately 227,447,000 kg CO2e, fall under Scope 3, which encompasses indirect emissions in the value chain. Notably, significant contributors to Scope 3 emissions include purchased goods and services (about 183,781,000 kg CO2e) and business travel (approximately 13,340,000 kg CO2e). In 2023, Argenx's total emissions were reported at around 433,353,000 kg CO2e, with Scope 1 emissions at 378,000 kg CO2e and Scope 2 emissions at approximately 189,000 kg CO2e (market-based). The Scope 3 emissions for that year were significantly higher, at about 432,786,000 kg CO2e, primarily driven by purchased goods and services. Currently, Argenx has not set specific reduction targets or initiatives, nor do they participate in the Science Based Targets initiative (SBTi). Their emissions data is not cascaded from any parent organization, indicating that the figures are independently reported. As the company continues to grow, it may consider establishing climate commitments to align with industry standards and expectations.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 378,000 | 0,000,000 |
| Scope 2 | 189,000 | 000,000 |
| Scope 3 | 432,786,000 | 000,000,000 |
Argenx's Scope 3 emissions, which decreased by 47% last year and decreased by approximately 47% since 2023, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 81% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Argenx has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
